Enanta, AbbVie deal

Enanta announced it will not exercise its option to co-develop HCV candidate ABT-493 in the U.S. The option would have allowed Enanta to fund 40% of development and U.S. commercialization costs and receive 40% of the profits from regimens containing the HCV therapy. Enanta and Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.) discovered the next-generation HCV NS3/4A protease inhibitor under a 2006 deal. Abbott spun out its pharmaceuticals business into AbbVie in January 2013. ABT-493 is in two Phase II trials in combination with HCV NS5A protein inhibitor ABT-530 to treat multiple genotypes of HCV infection. ...